Publications by authors named "Syeda Parsa"
Remimazolam for sedation in gastrointestinal endoscopy: A comprehensive review.
World J Gastrointest Endosc
July 2024
Article Synopsis
- Most routine endoscopic procedures use sedation for patient comfort, with Propofol, benzodiazepines, and opioids being popular choices, but Remimazolam is emerging as a new option since its FDA approval in July 2020.
- Remimazolam is an ultra-short-acting benzodiazepine with favorable pharmacological properties, showing non-inferior efficacy compared to Propofol while having fewer side effects like hemodynamic instability and respiratory depression.
- This review explores Remimazolam's characteristics, effectiveness, and safety, suggesting it could be a safer and more efficient alternative for procedural sedation in gastrointestinal endoscopy.